Several clinical studies implicated oxidative stress in the pathophysiology of both psychosis and dementia. As dementia is commonly associated with psychosis, antipsychotic medications are of importance in the pharmacotherapy of dementia particularly as a number of antipsychotics were reported to demonstrate neuronal pro-oxidant and/or antioxidant properties. Impairment of learning and memory, as the most characteristic manifestation of dementia, could be induced in experimental animals by acute administration of scopolamine (SCO) with a resultant elevation in brain oxidative status. This study investigated the potential pro-oxidant and/or antioxidant activity of the antipsychotic drug zuclopenthixol acetate, as its effect on brain oxidative status has yet to be evaluated. A 2×3 between-subjects factorial design was used to investigate the simultaneous and interactive effects of zuclopenthixol (0.7 and 1.4 mg/kg i.p.) and SCO on rat brain malondialdehyde, glutathione, glutathione peroxidase and superoxide dismutase levels/activities. Results revealed a significant pro-oxidant effect for both zuclopenthixol and SCO alone conditions. In addition, combined treatment of zuclopenthixol and SCO was found to be significantly different compared to either treatment conditions with regard to their effect on different brain oxidative stress indices. Such findings may have valuable implications in the pharmacotherapy of both psychosis and dementia.
1 Reddy RD , Yao JK . Free radical pathology in schizophrenia: a review . Prostaglandins Leukot Essent Fatty Acids1996; 55: 33-43 .
2.
2 Herken H , Uz E , Ozyurt H , Sogut S , Virit O , Akyol O . Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia . Mol Psychiatry2001; 6: 66-73 .
3.
3 Mahadik SP , Evans D , Lal H . Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia . Prog Neuropsychopharmacol Biol Psychiatry2001; 25: 463-493 .
4.
4 Yao JK , Reddy RD , van Kammen DP . Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications . CNS Drugs2001; 15: 287-310 .
5.
5 Andreassen OA , Weber C , Jorgensen HA . Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats . Pharmacol Biochem Behav1999; 64: 637-642 .
6.
6 Mahadik SP , Mukherjee S . Free radical pathology and antioxidant defense in schizophrenia: a review . Schizophr Res1996; 19: 1-17 .
7.
7 Behl C , Lezoulac'h F , Widmann M , Rupprecht R , Holsboer F . Oxidative stress-resistant cells are protected against haloperidol toxicity . Brain Res1996; 717: 193-195 .
8.
8 Eranti VS , Gangadhar BN , Janakiramaiah N . Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E . Psychopharmacology (Berl)1998; 140: 418-420 .
9.
9 Sagara Y . Induction of reactive oxygen species in neurons by haloperidol . J Neurochem1998; 71: 1002-1012 .
10.
10 Jeding I , Evans PJ , Akanmu D , Dexter D , Spencer JD , Aruoma OI , Jenner P , Halliwell B . Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs . Biochem Pharmacol1995; 49: 359-365 .
11.
11 Dalla Libera A , Scutari G , Boscolo R , Rigobello MP , Bindoli A . Antioxidant properties of clozapine and related neuroleptics . Free Radic Res1998; 29: 151-157 .
12.
12 Hara S , Endo T , Kuriiwa F , Kano S , Iwata N . Anti-oxidant effect of calmodulin antagonists in rat brain homogenate . Res Commun Chem Pathol Pharmacol1992; 76: 367-370 .
13.
13 Kagan VE , Prilipko LL , Savov VM . Formation of inhibitors of lipid peroxidation during oxidative metabolism of hydrophobic xenobiotics catalyzed by mixed function oxidases . Acta Physiol Pharmacol Bulgarica1984; 10: 46-56 .
14.
14 Cruz R , Almaguer Melian W , Bergado Rosado JA . Glutathione in cognitive function and neurodegeneration . Rev Neurol2003; 36: 877-886 .
15.
15 Deary IJ . Individual differences in cognition: British contributions over a century . Br J Psychol2001; 92: 217-238 .
16.
16 Misane I , Ogren SO . Selective 5-HT(1A) antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat . Neuropsychopharmacology2003; 28: 253-264 .
17.
17 Bejar C , Wang R , Weinstock M . Effect of rivastigmine on scopolamine-induced memory impairment in rats . Eur J Pharmacol1999; 383: 231-240 .
18.
18 Mishima K , Tsukikawa H , Miura I , Inada K , Abe K , Matsumoto Y , Egashira N , Iwasaki K , Fujiwara M . Ameliorative effect of NC-1900, a new AVP(4-9) analog, through vasopressin V(1A) receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze . Neuropharmacology2003; 44: 541-552 .
19.
19 Rubaj A , Zgodzinski W , Sieklucka-Dziuba M . The influence of adenosine A3 receptor agonist: IBMECA, on scopolamine-and MK-801-induced memory impairment . Behav Brain Res2003; 141: 11-17 .
20.
20 El-Sherbiny DA , Khalifa AE , Attia AS , Eldenshary ES . Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine . Pharmacol Biochem Behav2003; 76: 525-533 .
21.
21 Ilic TV , Jovanovic M , Jovicic A , Tomovic M . Oxidative stress indicators are elevated in de novo Parkinson's disease patients . Funct Neurol1999; 14: 141-147 .
22.
22 Bharath S , Hsu M , Kaur D , Rajagopalan S , Andersen JK . Glutathione, iron and Parkinson's disease . Biochem Pharmacol2002; 64: 1037-1048 .
23.
23 Dringen R , Hirrlinger J . Glutathione pathways in the brain . Biol Chem2003; 384: 505-516 .
24.
24 Maier CM , Chan PH . Role of superoxide dismutases in oxidative damage and neurodegenerative disorders . Neuroscientist2002; 8: 323-334 .
25.
25 Romain JL , Dermain P , Gresle P , Grignon S , Moisan P , Nore D , Pech G , Benyaya J , Perret I . Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study . Encephale1996; 22: 280-286 .
26.
26 Otani K , Aoshima T . Pharmacogenetics of classical and new antipsychotic drugs . Ther Drug Monit2000; 22: 118-121 .
27.
27 Paget GE , Barnes JM . Interspecies dosage conversion scheme in evaluation of results and quantitative application in different species. In Laurence DR , Bacharach AL eds. Evaluation of drug activities: pharmacometrics, Volume 1. London and New York: Academic Press , 1964: 160-167.
28.
28 Wanibuchi F , Nishida T , Yamashita H , Hidaka K , Koshiya K , Tsukamoto S , Usuda S . Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in-vivo pharmacological studies . Eur J Pharmacol1994; 265: 151-158 .
29.
29 Manzaneque JM , Navarro JF . An ethnopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice . Meth Findings Exp Clin Pharmacol1999; 21: 11-15 .
30.
30 Uchiyama M , Mihara M . Determination of malonaldehyde precursor in tissues by thiobarbituric acid test . Anal Biochem1978; 86: 271-278 .
32 Paglia DE , Valentine WN . Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase . J Lab Clin Med1967; 70: 158-169 .
33.
33 Marklund S , Marklund G . Involvement of the super-oxide anion radical in the autooxidation of Pyrogallol and a convenient assay for Superoxide dismutase . Eur J Biochem1974; 47: 469-474 .
34.
34 Post A , Holsboer F , Behl C . Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants . J Neurosci1998; 18: 8236-8246 .
35.
35 Shivakumar BR , Ravindranath V . Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol . Brain Res1992; 595: 256-262 .
36.
36 Tsai G , Goff DC , Chang RW , Flood J , Baer L , Coyle JT . Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia . Am J Psychiatry1998; 155: 1207-1213 .
37.
37 Spina MB , Cohen G . Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione . J Pharmacol Exp Ther1988; 247: 502-507 .
38.
38 Dollery C , Boobis AR , Burley D . Zuclopenthixol. Therapeutic drugs. Edinburgh: Churchill Livingstone , 1991: 209-214.
39.
39 Anden NE , Butcher SG , Corrodi H , Fuxe K , Ungerstedt U . Receptor activity and turnover of dopamine and noradrenaline after neuroleptics . Eur J Pharmacol1970; 11: 303-314 .
40.
40 Modi PI , Kashyap A , Nair VD , Ross GM , Fu M , Savelli JE , Marcotte ER , Barlas C , Mishra RK . Modulation of brain catecholamine absorbing proteins by dopaminergic agents . Eur J Pharmacol1996; 299: 213-220 .
41.
41 Thomas EA , George RC , Danielson PE , Nelson PA , Warren AJ , Lo D , Sutcliffe JG . Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins . Mol Psychiatry2003; 8: 983-993 .
42.
42 Hashimoto M , Hashimoto T , Kuriyama K . Protective effect of WEB 1881 FU on AF64A (ethylcholine aziridinium ion)-induced impairment of hippocampal cholinergic neurons and learning acquisition . Eur J Pharmacol1991; 209: 9-14 .
43.
43 Gulyaeva NV , Lazareva NA , Libe ML , Mitrokhina OS , Onufriev MV , Stepanichev MY , Chernysevskaya IA , Walsh TJ . Oxidative stress in the brain following intraventricular administration of ethylcholine aziridinium (AF64A) . Brain Res1996; 726: 174-180 .
44.
44 Naarala J , Tervo P , Loikkanen J , Savolainen K . Cholinergic-induced production of reactive oxygen species in human neuroblastoma cells . Life Sci1997; 60: 1905-1914 .
45.
45 Hiramatsu M , Murasawa H , Mori H , Kameyama T . Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous kappa-opioid receptor agonist . Br J Pharmacol1998; 123: 920-926 .
46.
46 Kvaltinova Z , Juranek I , Machova J , Stolc S . Effect of oxidative stress on (3H)-N-methylscopolamine binding and production of thiobarbituric acid reactive substances in rat cerebral cortex membranes . Gen Physiol Biophys1993; 12: 155-161 .
47.
47 El-Etri MM , Ennis M , Jiang M , Shipley MT . Pilocarpine-induced convulsions in rats: evidence for muscarinic receptor-mediated activation of locus coeruleus and norepinephrine release in cholinolytic seizure development . Exp Neurol1993; 121: 24-39 .
48.
48 Hrbek J , Rypka M . Effects of single administration of scopolamine, physostigmine and their combination on biogenic amine levels in rat brain . Acta Univ Palacki Olomuc Fac Med1990; 121: 271-275 .
